File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Conference Paper: Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
  • Basic View
  • Metadata View
  • XML View
TitleWeek 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
 
AuthorsLai, CL
Ahh, SH
Lee, KS
Um, SH
Cho, M
Yoon, SK
Lee, JW
Park, NH
Kweon, YO
Sohn, JH
Lee, J
Kim, JA
Han, KH
Yuen, MF
 
KeywordsMedical sciences
Gastroenterology
 
Issue Date2011
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
CitationThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.24666
 
AbstractBACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for …
 
DescriptionThis journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011
Poster Presentation
 
ISSN0270-9139
2013 Impact Factor: 11.190
 
DOIhttp://dx.doi.org/10.1002/hep.24666
 
DC FieldValue
dc.contributor.authorLai, CL
 
dc.contributor.authorAhh, SH
 
dc.contributor.authorLee, KS
 
dc.contributor.authorUm, SH
 
dc.contributor.authorCho, M
 
dc.contributor.authorYoon, SK
 
dc.contributor.authorLee, JW
 
dc.contributor.authorPark, NH
 
dc.contributor.authorKweon, YO
 
dc.contributor.authorSohn, JH
 
dc.contributor.authorLee, J
 
dc.contributor.authorKim, JA
 
dc.contributor.authorHan, KH
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2012-10-18T08:51:56Z
 
dc.date.available2012-10-18T08:51:56Z
 
dc.date.issued2011
 
dc.description.abstractBACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for …
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionThis journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011
 
dc.descriptionPoster Presentation
 
dc.description.otherThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24
 
dc.identifier.citationThe 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24 [How to Cite?]
DOI: http://dx.doi.org/10.1002/hep.24666
 
dc.identifier.doihttp://dx.doi.org/10.1002/hep.24666
 
dc.identifier.epage1442A
 
dc.identifier.hkuros211200
 
dc.identifier.hkuros211046
 
dc.identifier.issn0270-9139
2013 Impact Factor: 11.190
 
dc.identifier.issuesuppl. 1
 
dc.identifier.spage1442A
 
dc.identifier.urihttp://hdl.handle.net/10722/169370
 
dc.identifier.volume54
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology
 
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.
 
dc.subjectMedical sciences
 
dc.subjectGastroenterology
 
dc.titleWeek 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Lai, CL</contributor.author>
<contributor.author>Ahh, SH</contributor.author>
<contributor.author>Lee, KS</contributor.author>
<contributor.author>Um, SH</contributor.author>
<contributor.author>Cho, M</contributor.author>
<contributor.author>Yoon, SK</contributor.author>
<contributor.author>Lee, JW</contributor.author>
<contributor.author>Park, NH</contributor.author>
<contributor.author>Kweon, YO</contributor.author>
<contributor.author>Sohn, JH</contributor.author>
<contributor.author>Lee, J</contributor.author>
<contributor.author>Kim, JA</contributor.author>
<contributor.author>Han, KH</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2012-10-18T08:51:56Z</date.accessioned>
<date.available>2012-10-18T08:51:56Z</date.available>
<date.issued>2011</date.issued>
<identifier.citation>The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24</identifier.citation>
<identifier.issn>0270-9139</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/169370</identifier.uri>
<description>This journal suppl. contain abstracts of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2011</description>
<description>Poster Presentation</description>
<description.abstract>BACKGROUND: LB80380, a novel nucleotide analogue, is effective and safe in chronic hepatitis B(CHB) patients with lamivudine-resistant mutations, with doses above 90 mg daily. AIM: To compare the efficacy and safety of LB80380 with entecavir in treatment-naive CHB patients up to week 48 of therapy. METHODS: 115 CHB patients fulfilling the following criteria were recruited from Hong Kong and Korea: (1) HBsAg positive for &#8230;</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www.hepatology.org/</publisher>
<relation.ispartof>Hepatology</relation.ispartof>
<rights>Hepatology. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject>Medical sciences</subject>
<subject>Gastroenterology</subject>
<title>Week 48 analysis of a Phase IIB study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic Hepatitis B</title>
<type>Conference_Paper</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1002/hep.24666</identifier.doi>
<identifier.hkuros>211200</identifier.hkuros>
<identifier.hkuros>211046</identifier.hkuros>
<identifier.volume>54</identifier.volume>
<identifier.issue>suppl. 1</identifier.issue>
<identifier.spage>1442A</identifier.spage>
<identifier.epage>1442A</identifier.epage>
<publisher.place>United States</publisher.place>
<description.other>The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA., 4-8 November 2011. In Hepatology, 2011, v. 54 suppl. 1, p. 1442A-1442A, abstract no. LB-24</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/169370/1/re01.htm</bitstream.url>
</item>